Competition heats up in BCMA CAR-T as J&J, BMS update myelom...

Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, accord

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

J&J defends Darzalex with FDA approval for faster dosing

BMS' big merger bet is still on with latest CAR-T filing

Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b

Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.

BMS/AbbVie's combo falls short in untreated multiple myeloma...

Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown.